U.S. Stocks Move | Biogen (BIIB.US) rises over 5% as Q2 revenue and earnings per share beat expectations

According to Jinse Finance APP, on Wednesday, the share price of Biogen (BIIB.US) rose by more than 5% as of press time. In terms of news, the company’s second-quarter revenue increased by 3.8% year-on-year to $2.7 billion, surpassing expectations by $240 million; earnings per share were $3.60, exceeding forecasts by $1.57. Driven by the sales growth of newly acquired kidney and ophthalmic disease drugs, Biogen successfully offset the impact of declining revenue from multiple sclerosis (MS) drugs. The company’s quarterly revenue and adjusted earnings both exceeded analysts’ expectations.